Condition
Pancancer
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Enrolling By Invitation2
Unknown1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07157618RecruitingPrimary
Prospective Pathology Foundation Models
NCT07269236Enrolling By InvitationPrimary
Prospective Real-World Study of Multimodal AI
NCT07239297Enrolling By InvitationPrimary
Retrospective Pathology Foundation Models
NCT05308784UnknownPrimary
A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients
Showing all 4 trials